Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4069-4071

  Korba, Brent E ^a   Elazar, Menashe ^b   Lui, Ping ^b   Rossignol, Jean François ^b,c   Glenn, Jeffrey S ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Romark Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLCYTIDINE; CYTIDINE DERIVATIVE; NITAZOXANIDE; PEGINTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TIZOXANIDE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CELL LINE; CYTIDINE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; REPLICON; RIBAVIRIN; THIAZOLES; VIRUS REPLICATION;

EID: 55849149779     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00078-08     Document Type: Article

References (11)

1. Reference deleted.
2. Elazar, M., K. H. Cheong, P. Liu, H. B. Greenberg, C. M. Rice, and J. S. Glenn. 2003. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J. Virol. 77:6055-6061.
3. Fox, L. M., and L. D. Saravolatz. 2005. Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40:1173-1180.
4. Korba, B. E., A. B. Montero, K. Farrar, K. Gaye, S. Mukerjee, M. S. Ayers, and J. F. Rossignol. 2008. Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir. Res. 77:56-63.
5. Okuse, C., J. A. Rinaudo, K. Farrar, F. Wells, and B. E. Korba. 2005. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antivir. Res. 65:23-34.
6. Pankuch, G. A., and P. C. Appelbaum. 2006. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic bacteria. Antimicrob. Agents Chemother. 50:1112-1117.
7. Pierra, C., S. Benzaria, A. Amador, A. Moussa, S. Mathieu, R. Storer, and G. Gosselin. 2005. NM283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24:767-770.
8. Rossignol, J. F., A. Elfert, Y. El-Gohary, E. B. Keeffe, and J. S. Glenn. 2007. Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Hepatol. 46(Suppl. 1):316A-317A.
9. Rossignol, J. F., and Y. El-Gohary. 2006. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind, placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24:1423-1430.
10. Rossignol, J. F., M. Abu-Zekry, A. Hussein, and M. G. Santoro. 2006. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368:124-129.
11. Zhou, Y., U. Müh, B. L. Hanzelka, D. J. Bartels, Y. Wei, B. G. Rao, D. L. Brennan, A. M. Tigges, L. Swenson, A. D. Kwong, and C. Lin. 2007. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 282:22619-22628.